Sortina Pharma develops small molecule therapeutics that target sortilin to eliminate treatment-resistant cancer stem cells, specifically focusing on triple-negative breast cancer and glioblastoma multiforme. This approach aims to prevent metastasis and enhance the efficacy of conventional therapies, addressing the critical challenge of cancer progression.
Funding
Funding not disclosed
Founders
Product
Problem
Many cancers, such as triple-negative breast cancer and glioblastoma multiforme, contain treatment-resistant cancer stem cells that drive metastasis and reduce the effectiveness of conventional therapies. Eliminating these stem cells is crucial to preventing cancer progression and improving patient outcomes.
Solution
Sortina Pharma is developing small molecule therapeutics that target sortilin, a protein implicated in cancer progression and neurodegenerative disorders. By inhibiting sortilin, their approach aims to eliminate treatment-resistant cancer stem cells, preventing the spread of cancer and enhancing the efficacy of existing therapies. Sortina's oral small molecule drugs offer a scalable technology platform applicable to various cancers and central nervous system (CNS) indications. The company's strategy involves developing optimal small molecules targeting sortilin, creating a pipeline covering cancer and CNS indications, and seeking partnerships throughout the development process.
Target Audience
The primary target audience includes patients with cancers driven by sortilin, such as Glioblastoma Multiforme and triple-negative breast cancer, as well as pharmaceutical companies interested in partnering to develop novel cancer and neurodegenerative disease therapies.
Features
- Oral small molecule therapeutics targeting sortilin
- Focus on eliminating treatment-resistant cancer stem cells
- Strong IP covering chemical structures
- First-in-class cancer treatment approach
- Cost-effective manufacturing
- Scalable technology applicable to various cancers and CNS indications
- Biomarkers for patient selection and treatment monitoring